Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hengrui Launches Luzsana to Bring its Novel Medications to Global Markets

publication date: May 18, 2022

Jiangsu Hengrui Pharma launched a new global company, Luzsana Biotechnology, devoted to making its most advanced medications available and affordable in global markets. For 25 years, Hengrui has been developing novel drugs, with a portfolio of 250 clinical studies for unmet needs in oncology, cardiovascular, metabolic/diabetes, pain management, immunology and liver/renal disease. Initially, the company will co-develop 11 of Hengrui’s candidates that range from preclinical to Phase III stage. All the candidates have first-in-class or best-in-class potential, the company said. Luzsana is headquartered in Princeton, NJ with facilities in Basel and Tokyo. More details....

Stock Symbol: (SHA: 600275)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital